Intermittent androgen deprivation therapy: redefining the standard of care?

Primary tabs

field_vote: 
Average: 10 (1 vote)
Disease(s): 
Therapeutic intervention: 
Therapeutic Substance(s): 
Publication type: 

Rev Urol. 2010
Winter;12(1):1-11.
Intermittent androgen
deprivation therapy: redefining the standard of care?
Shore
ND
, Crawford
ED
.

Abstract
As
a clinical strategy, intermittent androgen deprivation therapy (IADT)
has the potential to minimize adverse events associated with continuous
androgen deprivation therapy while providing comparable efficacy for
patients with advanced prostate cancer. Because most studies supporting
IADT to date have been somewhat small and underpowered, additional
large, randomized, controlled trials are needed before this strategy
becomes the standard of care. However, the potential advantages of IADT,
which include improved quality of life, the theoretical possibility of
delaying hormone resistance, and possible reduction in expenses to the
patient and health care payers, suggest it is a strategy worth further
exploration.